Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications

Fig. 3

Associations of ABx and CS over time and by drug class. a Hazard ratios with 95% confidence intervals of a Cox Proportional-Hazards model comparing individuals treated with ABx or CS during a 30-day sliding window compared to indivduals who did not receive ABx or CS, respectively. The significance and direction of associations of Cox Proportional Hazards models by (b) ABx or (c) CS class and cancer, using a window 28 days around ICI treatment start

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us